Targeting neutrophils for host-directed therapy to treat tuberculosis

International Journal of Medical Microbiology

Volumn 308, Issue 1, 2018, Pages 142-147

  Dallenga, Tobias ^a,b   Linnemann, Lara ^a   Paudyal, Bhesh ^a   Repnik, Urska ^c   Griffiths, Gareth ^c   Schaible, Ulrich E ^a,b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b German Center for Infection Research   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

CD1; Host directed therapy; Mycobacterium tuberculosis; Neutrophil; Small lipid mediators; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIGEN; CD1 ANTIGEN; MEMBRANE PHOSPHOLIPID; TUBERCULOSTATIC AGENT; LIPID;

ANTIBIOTIC THERAPY; DRUG EFFICACY; HOST DIRECTED THERAPY; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; LEUKOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; REVIEW; TARGET CELL; TUBERCULOSIS; ANIMAL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; LIPIDS; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL INFILTRATION; NEUTROPHILS; TUBERCULOSIS;

EID: 85031675090     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2017.10.001     Document Type: Review

References (71)

1. Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., DE Jong, B.C., Koul, A., Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One, 9, 2014, e102135.
2. Apt, A., Kramnik, I., Man and mouse TB: contradictions and solutions. Tuberculosis (Edinb) 89 (2009), 195–198.
3. Bafica, A., Scanga, C.A., Serhan, C., Machado, F., White, S., Sher, A., Aliberti, J., Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 115 (2005), 1601–1606.
4. Baghaei, P., Tabarsi, P., Dorriz, D., Marjani, M., Shamaei, M., Pooramiri, M.V., Mansouri, D., Farnia, P., Masjedi, M., Velayati, A., Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am. J. Ther. 18 (2011), e29–34.
5. Bell, R.L., Young, P.R., Albert, D., Lanni, C., Summers, J.B., Brooks, D.W., Rubin, P., Carter, G.W., The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int. J. Immunopharmacol. 14 (1992), 505–510.
6. Berger, W., DE Chandt, M.T., Cairns, C.B., Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61 (2007), 663–676.
7. Berry, M.P., Graham, C.M., Mcnab, F.W., Xu, Z., Bloch, S.A., Oni, T., Wilkinson, K.A., Banchereau, R., Skinner, J., Wilkinson, R.J., Quinn, C., Blankenship, D., Dhawan, R., Cush, J.J., Mejias, A., Ramilo, O., Kon, O.M., Pascual, V., Banchereau, J., Chaussabel, D., O'garra, A., An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 (2010), 973–977.
8. Bjornsdottir, H., Welin, A., Michaelsson, E., Osla, V., Berg, S., Christenson, K., Sundqvist, M., Dahlgren, C., Karlsson, A., Bylund, J., Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic. Biol. Med. 89 (2015), 1024–1035.
9. Cardona, P.J., Gordillo, S., Diaz, J., Tapia, G., Amat, I., Pallares, A., Vilaplana, C., Ariza, A., Ausina, V., Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 71 (2003), 5845–5854.
10. Carlin, G., Djursater, R., Peroxidation of phospholipids promoted by myeloperoxidase. Free Radic. Res. Commun. 4 (1988), 251–257.
11. Claster, S., Chiu, D.T., Quintanilha, A., Lubin, B., Neutrophils mediate lipid peroxidation in human red cells. Blood 64 (1984), 1079–1084.
12. Coffey, M.J., Phare, S.M., Peters-Golden, M., Role of leukotrienes in killing of Mycobacterium bovis by neutrophils. Prostaglandins Leukot Essent Fatty Acids 71 (2004), 185–190.
13. Corleis, B., Korbel, D., Wilson, R., Bylund, J., Chee, R., Schaible, U.E., Escape of Mycobacterium tuberculosis from oxidative killing by neutrophils. Cell. Microbiol. 14 (2012), 1109–1121.
14. Cuzzocrea, S., Rossi, A., Mazzon, E., DI Paola, R., Genovese, T., Muia, C., Caputi, A.P., Sautebin, L., 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab. Invest. 85 (2005), 808–822.
15. Dallenga, T., Schaible, U.E., Neutrophils in tuberculosis–first line of defence or booster of disease and targets for host-directed therapy?. Pathog. Dis., 74, 2016.
16. Dallenga, T., Repnik, U., Corleis, B., Eich, J., Reimer, R., Griffiths, G.W., Schaible, U.E., M. tuberculosis-Induced Necrosis of Infected Neutrophils Promotes Bacterial Growth Following Phagocytosis by Macrophages. Cell Host Microbe 22 (2017), 519–530 e3.
17. Dheda, K., Gumbo, T., Maartens, G., Dooley, K.E., Mcnerney, R., Murray, M., Furin, J., Nardell, E.A., London, L., Lessem, E., Theron, G., Van Helden, P., Niemann, S., Merker, M., Dowdy, D., Van Rie, A., Siu, G.K., Pasipanodya, J.G., Rodrigues, C., Clark, T.G., Sirgel, F.A., Esmail, A., Lin, H.H., Atre, S.R., Schaaf, H.S., Chang, K.C., Lange, C., Nahid, P., Udwadia, Z.F., Horsburgh, C.R. Jr., Churchyard, G.J., Menzies, D., Hesseling, A.C., Nuermberger, E., Mcilleron, H., Fennelly, K.P., Goemaere, E., Jaramillo, E., Low, M., Jara, C.M., Padayatchi, N., Warren, R.M., The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med.(15), 2017 pii: S2213-2600(17)30079-6.
18. Dorhoi, A., Kaufmann, S.H., Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation. Eur. J. Immunol. 45 (2015), 2191–2202.
19. Driver, E.R., Ryan, G.J., Hoff, D.R., Irwin, S.M., Basaraba, R.J., Kramnik, I., Lenaerts, A.J., Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56 (2012), 3181–3195.
20. Eum, S.Y., Kong, J.H., Hong, M.S., Lee, Y.J., Kim, J.H., Hwang, S.H., Cho, S.N., Via, L.E., Barry, C.E. 3rd, Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137 (2010), 122–128.
21. Flower, R., Prostaglandins, bioassay and inflammation. Br. J. Pharmacol. 147 (2006), S182–92.
22. Gadola, S.D., Zaccai, N.R., Harlos, K., Shepherd, D., Castro-Palomino, J.C., Ritter, G., Schmidt, R.R., Jones, E.Y., Cerundolo, V., Structure of human CD1b with bound ligands at 2.3 Å: a maze for alkyl chains. Nat. Immunol. 3 (2002), 721–726.
23. Gopal, R., Monin, L., Torres, D., Slight, S., Mehra, S., Mckenna, K.C., Fallert Junecko, B.A., Reinhart, T.A., Kolls, J., Baez-Saldana, R., Cruz-Lagunas, A., Rodriguez-Reyna, T.S., Kumar, N.P., Tessier, P., Roth, J., Selman, M., Becerril-Villanueva, E., Baquera-Heredia, J., Cumming, B., Kasprowicz, V.O., Steyn, A.J., Babu, S., Kaushal, D., Zuniga, J., Vogl, T., Rangel-Moreno, J., Khader, S.A., S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am. J. Respir. Crit. Care Med. 188 (2013), 1137–1146.
24. Hamberg, M., Svensson, J., Samuelsson, B., Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U. S. A. 72 (1975), 2994–2998.
25. Harper, J., Skerry, C., Davis, S.L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W.R., Pomper, M.G., Nuermberger, E.L., Jain, S.K., Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205 (2012), 595–602.
26. Hebert, M.J., Takano, T., Holthofer, H., Brady, H.R., Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J. Immunol. 157 (1996), 3105–3115.
27. Heinecke, J.W., Li, W., Mueller, D.M., Bohrer, A., Turk, J., Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry 33 (1994), 10127–10136.
28. Hoffmann, H., Kohl, T.A., Hofmann-Thiel, S., Merker, M., Beckert, P., Jaton, K., Nedialkova, L., Sahalchyk, E., Rothe, T., Keller, P.M., Niemann, S., Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am. J. Respir. Crit. Care Med. 193 (2016), 337–340.
29. Huang, S., Cheng, T.-Y., Young, D.C., Layre, E., Madigan, C.A., Shires, J., Cerundolo, V., Altman, J.D., Moody, D.B., Discovery of deoxyceramides and diacylglycerols as CD1b scaffold lipids among diverse groove-blocking lipids of the human CD1 system. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 19335–19340.
30. Irwin, S.M., Gruppo, V., Brooks, E., Gilliland, J., Scherman, M., Reichlen, M.J., Leistikow, R., Kramnik, I., Nuermberger, E.L., Voskuil, M.I., Lenaerts, A.J., Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob. Agents Chemother. 58 (2014), 4026–4034.
31. De Jong, A., Cheng, T.-Y., Huang, S., Gras, S., Birkinshaw, W., Kasmar, A., Rhijn, I.V., Peña-Cruz, V., Ruan, D.T., Altman, J.D., Rossjohn, J., Moody, D.B., CD1a-autoreactive T cells recognize natural skin oils that function as headless antigens. Nat. Immunol. 15 (2014), 177–185.
32. Keller, C., Hoffmann, R., Lang, R., Brandau, S., Hermann, C., Ehlers, S., Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect. Immun. 74 (2006), 4295–4309.
33. Kimmey, J.M., Huynh, J.P., Weiss, L.A., Park, S., Kambal, A., Debnath, J., Virgin, H.W., Stallings, C.L., Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature 528 (2015), 565–569.
34. Kramnik, I., Demant, P., Bloom, B.B., Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found. Symp. 217 (1998), 120–131 discussion 132-7.
35. Kramnik, I., Dietrich, W.F., Demant, P., Bloom, B.R., Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 8560–8565.
36. Lanoix, J.P., Lenaerts, A.J., Nuermberger, E.L., Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis. Model Mech. 8 (2015), 603–610.
37. Lemos, H.P., Grespan, R., Vieira, S.M., Cunha, T.M., Verri, W.A. Jr., Fernandes, K.S., Souto, F.O., Mcinnes, I.B., Ferreira, S.H., Liew, F.Y., Cunha, F.Q., Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 5954–5959.
38. Libero, G.D., Mori, L., The T-cell response to lipid antigens of Mycobacterium tuberculosis. Front. Immunol., 5, 2014 1–1.
39. Major, S., Turner, J., Beamer, G., Tuberculosis in CBA/J mice. Vet. Pathol. 50 (2013), 1016–1021.
40. Marks, S.M., Hirsch-Moverman, Y., Salcedo, K., Graviss, E.A., Oh, P., Seaworth, B., Flood, J., Armstrong, L., Armitige, L., Mase, S., Consortium, T.B.E.S., Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005–2007. Int. J. Tuberc. Lung Dis. 20 (2016), 435–441.
41. Mayer-Barber, K.D., Andrade, B.B., Oland, S.D., Amaral, E.P., Barber, D.L., Gonzales, J., Derrick, S.C., Shi, R., Kumar, N.P., Wei, W., Yuan, X., Zhang, G., Cai, Y., Babu, S., Catalfamo, M., Salazar, A.M., Via, L.E., Barry, C.E. 3rd, Sher, A., Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511 (2014), 99–103.
42. Medeiros, A.I., Silva, C.L., Malheiro, A., Maffei, C.M., Faccioli, L.H., Leukotrienes are involved in leukocyte recruitment induced by live Histoplasma capsulatum or by the beta-glucan present in their cell wall. Br. J. Pharmacol. 128 (1999), 1529–1537.
43. Medina, E., North, R.J., Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93 (1998), 270–274.
44. Mishra, B.B., Lovewell, R.R., Olive, A.J., Zhang, G., Wang, W., Eugenin, E., Smith, C.M., Phuah, J.Y., Long, J.E., Dubuke, M.L., Palace, S.G., Goguen, J.D., Baker, R.E., Nambi, S., Mishra, R., Booty, M.G., Baer, C.E., Shaffer, S.A., Dartois, V., Mccormick, B.A., Chen, X., Sassetti, C.M., Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat. Microbiol., 2, 2017, 17072.
45. Moody, D.B., Zajonc, D.M., Wilson, I.A., Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5 (2005), 387–399.
46. Nathan, C., Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6 (2006), 173–182.
47. Niki, E., Lipid peroxidation: physiological levels and dual biological effects. Free Radic. Biol. Med. 47 (2009), 469–484.
48. Nikonenko, B.V., Averbakh, M.M. Jr., Lavebratt, C., Schurr, E., Apt, A.S., Comparative analysis of mycobacterial infections in susceptible I/St and resistant A/Sn inbred mice. Tuber. Lung Dis. 80 (2000), 15–25.
49. Nourshargh, S., Mechanisms of neutrophil and eosinophil accumulation in vivo. Am. Rev. Respir. Dis. 148 (1993), S60–S64.
50. Palmblad, J.E., Lerner, R., Leukotriene B4-induced hyperadhesiveness of endothelial cells for neutrophils: relation to CD54. Clin. Exp. Immunol. 90 (1992), 300–304.
51. Pan, H., Yan, B.S., Rojas, M., Shebzukhov, Y.V., Zhou, H., Kobzik, L., Higgins, D.E., Daly, M.J., Bloom, B.R., Kramnik, I., Ipr1 gene mediates innate immunity to tuberculosis. Nature 434 (2005), 767–772.
52. Parida, S.K., Axelsson-Robertson, R., Rao, M.V., Singh, N., Master, I., Lutckii, A., Keshavjee, S., Andersson, J., Zumla, A., Maeurer, M., Totally drug-resistant tuberculosis and adjunct therapies. J. Intern. Med. 277 (2015), 388–405.
53. Pereira, C.S., Macedo, M.F., CD1-Restricted t cells at the crossroad of innate and adaptive immunity. J. Immunol. Res., 2016, 2016.
54. Pichugin, A.V., Yan, B.S., Sloutsky, A., Kobzik, L., Kramnik, I., Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174 (2009), 2190–2201.
55. Pooran, A., Pieterson, E., Davids, M., Theron, G., Dheda, K., What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?. PLoS One, 8, 2013, e54587.
56. Ramos-Kichik, V., Mondragon-Flores, R., Mondragon-Castelan, M., Gonzalez-Pozos, S., Muniz-Hernandez, S., Rojas-Espinosa, O., Chacon-Salinas, R., Estrada-Parra, S., Estrada-Garcia, I., Neutrophil extracellular traps are induced by Mycobacterium tuberculosis. Tuberculosis (Edinb) 89 (2009), 29–37.
57. Riedel, D.D., Kaufmann, S.H., Chemokine secretion by human polymorphonuclear granulocytes after stimulation with Mycobacterium tuberculosis and lipoarabinomannan. Infect. Immun. 65 (1997), 4620–4623.
58. Seiler, P., Aichele, P., Raupach, B., Odermatt, B., Steinhoff, U., Kaufmann, S.H., Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J. Infect. Dis. 181 (2000), 671–680.
59. Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (2008), 349–361.
60. Stelmaszynska, T., Kukovetz, E., Egger, G., Schaur, R.J., Possible involvement of myeloperoxidase in lipid peroxidation. Int. J. Biochem. 24 (1992), 121–128.
61. Toda, A., Yokomizo, T., Shimizu, T., Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat. 68–69 (2002), 575–585.
62. Torun, T., Gungor, G., Ozmen, I., Bolukbasi, Y., Maden, E., Bicakci, B., Atac, G., Sevim, T., Tahaoglu, K., Side effects associated with the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 9 (2005), 1373–1377.
63. Ulbrich, H., Eriksson, E.E., Lindbom, L., Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 24 (2003), 640–647.
64. Ulrichs, T., Moody, D.B., Grant, E., Kaufmann, S.H.E., Porcelli, S.A., T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect. Immun. 71 (2003), 3076–3087.
65. Van Rhijn, I., Moody, D.B., CD1 and mycobacterial lipids activate human T cells. Immunol. Rev. 264 (2015), 138–153.
66. Verma, S., Mahajan, V., Multiple side effects of second line antitubercular therapy In a single patient. Internet J. Pulm. Med., 9, 2007.
67. Vilaplana, C., Marzo, E., Tapia, G., Diaz, J., Garcia, V., Cardona, P.J., Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208 (2013), 199–202.
68. WHO, World Health Organization: Global Tuberculosis Report., 20th edition, 2016, WHO Press, Genova.
69. Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10 (2010), 181–193.
70. Wenzel, S.E., Kamada, A.K., Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacother. 30 (1996), 858–864.
71. Yeremeev, V., Linge, I., Kondratieva, T., Apt, A., Neutrophils exacerbate tuberculosis infection in genetically susceptible mice. Tuberculosis (Edinb) 95 (2015), 447–451.